ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E19.34 EPS (ttm)7.51 Insider Own0.11% Shs Outstand1.77B Perf Week-0.21%
Market Cap256.15B Forward P/E12.45 EPS next Y11.66 Insider Trans-2.12% Shs Float1.77B Perf Month-11.10%
Income13.34B PEG- EPS next Q3.57 Inst Own70.90% Short Float / Ratio0.68% / 2.19 Perf Quarter0.64%
Sales57.82B P/S4.43 EPS this Y137.00% Inst Trans0.10% Short Interest11.96M Perf Half Y5.29%
Book/sh9.03 P/B16.08 EPS next Y-15.27% ROA9.30% Target Price162.96 Perf Year3.28%
Cash/sh6.73 P/C21.56 EPS next 5Y-2.92% ROE85.60% 52W Range134.09 - 175.91 Perf YTD-10.07%
Dividend5.92 P/FCF21.22 EPS past 5Y12.20% ROI17.90% 52W High-17.38% Beta0.61
Dividend %4.08% Quick Ratio0.80 Sales past 5Y17.00% Gross Margin71.20% 52W Low8.39% ATR2.62
Employees50000 Current Ratio0.90 Sales Q/Q3.30% Oper. Margin30.60% RSI (14)31.37 Volatility1.67% 1.86%
OptionableYes Debt/Eq4.35 EPS Q/Q24.50% Profit Margin23.10% Rel Volume0.67 Prev Close145.20
ShortableYes LT Debt/Eq3.78 EarningsFeb 09 BMO Payout73.40% Avg Volume5.46M Price145.34
Recom2.30 SMA20-3.71% SMA50-7.91% SMA200-2.61% Volume272,065 Change0.10%
Nov-18-22Initiated Credit Suisse Outperform $170
Nov-08-22Downgrade Societe Generale Buy → Hold
Aug-01-22Downgrade Atlantic Equities Overweight → Neutral $178 → $162
May-23-22Initiated SVB Leerink Underperform $140
May-06-22Downgrade Daiwa Securities Outperform → Neutral $150
Apr-06-22Resumed Morgan Stanley Overweight $192
Feb-28-22Downgrade UBS Buy → Neutral $129 → $147
Feb-03-22Reiterated Goldman Neutral $117 → $122
Feb-03-22Reiterated BofA Securities Neutral $135 → $138
Feb-03-22Reiterated BMO Capital Markets Outperform $153 → $154
Show Previous Ratings
Feb-06-23 06:35AM
05:30AM
Feb-05-23 08:46AM
07:00AM
Feb-04-23 08:30AM
07:45AM Loading…
07:45AM
Feb-03-23 05:31PM
02:15PM
01:19PM
10:07AM
09:00AM
09:00AM
07:00AM
01:15AM
12:58AM
12:52PM Loading…
Feb-02-23 12:52PM
10:01AM
09:53AM
09:00AM
07:55AM
Feb-01-23 01:32PM
12:36PM
06:00AM
05:55AM
Jan-31-23 04:04PM
01:07PM
10:25AM
09:25AM
08:15AM
07:36AM
06:18AM Loading…
06:18AM
06:01AM
06:00AM
06:00AM
06:00AM
Jan-30-23 05:57PM
05:45PM
10:11AM
06:58AM
Jan-28-23 05:30AM
Jan-26-23 10:20AM
Jan-25-23 05:20PM
10:37AM
09:00AM
07:05AM
06:00AM
Jan-23-23 05:45PM
09:00AM
Jan-22-23 07:05PM
05:30AM
Jan-19-23 05:30AM
Jan-18-23 05:32PM
03:44PM
09:53AM
09:20AM
08:00AM
Jan-17-23 05:45PM
10:07AM
10:00AM
08:00AM
07:45AM
06:03AM
05:47AM
Jan-16-23 09:00AM
08:45AM
06:34AM
04:24AM
Jan-14-23 01:22PM
10:03AM
Jan-13-23 09:45AM
Jan-12-23 05:00AM
Jan-11-23 04:01PM
07:50AM
07:10AM
05:30AM
Jan-10-23 05:45PM
12:28PM
09:45AM
09:12AM
09:02AM
09:00AM
08:00AM
07:00AM
05:52AM
05:31AM
Jan-09-23 12:48PM
07:01AM
Jan-07-23 06:10AM
Jan-06-23 06:44PM
04:05PM
02:46PM
01:46PM
10:35AM
08:30AM
08:00AM
Jan-05-23 05:11PM
08:00AM
07:01AM
05:06AM
Jan-04-23 10:23AM
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RICHMOND TIMOTHY J.EVP, CHIEF HR OFFICERDec 12Option Exercise54.8642,3702,324,41856,207Dec 14 05:06 PM
RICHMOND TIMOTHY J.EVP, CHIEF HR OFFICERDec 12Sale163.4442,3706,925,01813,837Dec 14 05:06 PM
SEVERINO MICHAELVice ChairmanMay 23Option Exercise108.9979,8018,697,627231,904May 25 04:58 PM
SEVERINO MICHAELVice ChairmanMay 23Sale150.9079,80112,041,780152,103May 25 04:58 PM
SEVERINO MICHAELVice ChairmanMay 17Option Exercise88.38100,0008,837,929252,103May 18 05:12 PM
SEVERINO MICHAELVice ChairmanMay 17Sale154.04100,00015,404,400152,103May 18 05:12 PM
SEVERINO MICHAELVice ChairmanMay 16Option Exercise66.50100,0006,650,277252,103May 18 05:12 PM
Gosebruch Henry OEVP, Chief Strategy OfficerMay 16Option Exercise54.8683,9604,606,046100,583May 18 05:12 PM
Gosebruch Henry OEVP, Chief Strategy OfficerMay 16Sale155.0083,96013,013,80016,623May 18 05:12 PM
SEVERINO MICHAELVice ChairmanMay 16Sale154.45100,00015,445,089152,103May 18 05:12 PM
SEVERINO MICHAELVice ChairmanMay 10Option Exercise59.60100,0005,960,468252,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 10Sale152.28100,00015,227,966152,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 09Option Exercise56.21100,0005,621,478252,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 09Sale150.28100,00015,027,710152,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 06Option Exercise54.55100,0005,454,790252,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 06Sale150.81100,00015,080,612152,103May 10 05:05 PM
Stewart Jeffrey RyanEVP, Chief Commercial OfficerMar 24Option Exercise58.8827,6901,630,38788,631Mar 25 05:09 PM
Stewart Jeffrey RyanEVP, Chief Commercial OfficerMar 24Sale159.2027,6904,408,37560,941Mar 25 05:09 PM
Durkin Brian LVP, ControllerMar 09Option Exercise79.0211,682923,11237,722Mar 11 05:05 PM
Durkin Brian LVP, ControllerMar 09Sale150.0118,6282,794,30119,094Mar 11 05:05 PM
Gosebruch Henry OEVP, Chief Strategy OfficerMar 01Sale147.2925,0003,682,18916,623Mar 02 05:03 PM
Stewart Jeffrey RyanEVP, Chief Commercial OfficerMar 01Sale148.2521,4883,185,59960,941Mar 01 06:08 PM
Gosebruch Henry OEVP, Chief Strategy OfficerMar 01Sale148.2615,0002,223,83641,623Mar 01 06:14 PM
Michael Robert A.Vice ChairmanMar 01Sale148.2543,1056,390,24737,877Mar 01 06:07 PM
Strom Carrie CSVP & Pres Global Allerg AesthFeb 07Sale141.172,396338,24342,499Feb 08 05:13 PM